



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/729,193
		Filing Date	December 5, 2003
		First Named Inventor	Ping Wang
		Art Unit	1653
		Examiner Name	Suzanne M. Mayer, Ph.D.
Sheet 1 of 1	Attorney Docket Number	50425/187	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Smu	1	ELSASSER T.H. et al., "Adrenomedullin binding protein in the plasma of multiple species: characterization by radioligand blotting"; Endocrinol 140:4908-4911, 1999.	
Smu	2	SHINDO T. et al., "Hypotension and resistance to lipopolysaccharide-induced shock in transgenic mice overexpressing adrenomedullin in their vasculature"; Circulation 101:2309-2316, 2000.	
Smu	3	WICHTERMAN K.A. et al., "Sepsis and septic shock: a review of laboratory models and a proposal"; J Surg Res 29:189-201, 1980.	
Smu	4	WU R. et al., "Adrenomedullin and adrenomedullin binding protein-1 downregulate TNF-alpha in macrophage cell line and rat Kupffer cells"; Regul Pept 112:19-26, 2003.	
Smu	5	YANG S et al., "Novel approach to prevent the transition from the hyperdynamic phase to the hypodynamic phase of sepsis: The role of adrenomedullin and adrendomedullin binding protein-1"; Crit Care Med. 29 (12, Suppl.); abst. A12, December 2001.	
Smu	6	YANG S. et al., "Novel approach to prevent the transition from the hyperdynamic phase to the hypodynamic phase of sepsis: Role of adrenomedullin and adrendomedullin binding protein-1"; Ann Surg 236:625-633, 2002.	
Smu	7	YANG S. et al., "Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: down-regulation of proinflammatory cytokines"; Crit Care Med 30:2729-2735, 2002.	

Examiner Signature	<i>Suzanne M. Mayer</i>	Date Considered	12-6-2004
--------------------	-------------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.